Highlights Amniotics AB

Equities

AMNI

SE0015961016

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 EDT			5-day change	1st Jan Change
0.0055 ^SEK	-8.33%		+10.00%	-38.89%

05-20	Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other.	CI
03-22	Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Magle Chemoswed Holding AB (OM:MAGLE) cancelled the acquisition of 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other.	05-19	CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	03-21	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Amniotics Secures Orphan Designation for Lung Injury Therapy from European Commission	12-14	MT
Amniotics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-27	CI
Amniotics AB Receives Positive Opinion on Orphan Designation for PulmoStem from the European Medicines Agency for the Treatment of Primary Graft Dysfunction Following Lung Transplantation	11-20	CI
Amniotics AB Receives Final Clinical Study Report for the Phase Ib Clinical Trial	23-09-13	CI
Amniotics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Amniotics AB Announces Positive Interim Results with CogniStem	23-06-04	CI
Amniotics AB Receives Positive Topline Results from Clinical Phase Ib Study with PulmoStem	23-05-25	CI
Amniotics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Amniotics AB Receives Positive Information About Safety Data for PulmoStem in Clinical Study	23-03-02	CI
Amniotics AB Completes Phase Ib Study of PulmoStem	23-02-16	CI
Amniotics AB Reports Earnings Results for the Full Year Ended December 30, 2022	23-01-19	CI
Amniotics AB Reports Earnings Results for the Fourth Quarter Ended December 30, 2022	23-01-19	CI
Amniotics AB Receives Positive Safety Data from PulmoStem™ Clinical Study	22-12-19	CI
Amniotics-led Consortium Wins EU Grant for Anti-Cancer Cells Program	22-11-14	MT
Amniotics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Amniotics AB Announces First Patient Dosed in Phase Ib Study with PulmoStem to Treat Severe Viral Lung Disease	22-10-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amniotics AB

Equities

AMNI

SE0015961016

Highlights

Filters